An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
- Conditions
- Lung Diseases, Interstitial
- Registration Number
- NCT03843892
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
None
- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation in this Expanded Access Program (EAP).
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Banner University Medical Center Tucson
🇺🇸Tucson, Arizona, United States
The Lung Research Center, LLC
🇺🇸Chesterfield, Missouri, United States
Glacier View Research Institute
🇺🇸Kalispell, Montana, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
Centra Medical Group
🇺🇸Bedford, Virginia, United States
Inova Fairfax Medical Campus
🇺🇸Falls Church, Virginia, United States
Banner University Medical Center Tucson🇺🇸Tucson, Arizona, United States